ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

CEO

Mr. Eugene W. Williams

Employees

Country

Canada

ISIN

CA74346M4065

Listings

0 Comments

Share your thoughts

FAQ

What is ProMIS Neurosciences stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange ProMIS Neurosciences stocks are traded under the ticker 23J0.STU.

When is the next ProMIS Neurosciences earnings date?▼

ProMIS Neurosciences is going to release the next earnings report on August 17, 2026.

What were ProMIS Neurosciences earnings last quarter?▼

23J0.STU earnings for the last quarter are -1.07 EUR per share, whereas the estimation was -0.9 EUR resulting in a -18.87% surprise. The estimated earnings for the next quarter are N/A EUR per share.

What is ProMIS Neurosciences revenue for the last year?▼

ProMIS Neurosciences revenue for the last year amounts to 0 EUR.

What is ProMIS Neurosciences net income for the last year?▼

23J0.STU net income for the last year is -34.34M EUR.

How many employees does ProMIS Neurosciences have?▼

As of July 10, 2026, the company has 10 employees.

In which sector is ProMIS Neurosciences located?▼

ProMIS Neurosciences operates in the Health & Wellness sector.

When did ProMIS Neurosciences complete a stock split?▼

ProMIS Neurosciences has not had any recent stock splits.

Where is ProMIS Neurosciences headquartered?▼

ProMIS Neurosciences is headquartered in Toronto, Canada.